Kenneth L. Schaecher, MD, FACP, CPC
Associate Chief Medical Officer, University of Utah Health Plans
Attending Physician - Internal Medicine, Granger Medical Clinic
Salt Lake City, UT
Authored Items
Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Breast cancer is not simply one disease, and the use of more effective therapies that target different tumor markers, such as the cyclin-dependent kinase (CDK)4/6 pathway in estrogen receptor–positive breast cancer, may actually reduce the total cost of care for patients/members and payers.
Read More ›Conquering the Cancer Care Continuum - Series Three: Fourth Issue
The Affordable Care Act (ACA), officially called the Patient Protection and Affordable Care Act, which began implementation in March 2010 and will not be fully implemented until 2018, has impacted oncology care in both positive and negative ways. Read More ›